

GLAXOSMITHKLINE PLC  
Form 6-K  
July 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 July 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
    - a) Name Ms E Walmsley
    - b) Position/status Chief Executive Officer
    - c) Initial notification/  
amendment Initial notification
  2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
    - a) Name GlaxoSmithKline plc
    - b) LEI 5493000HZTVUYLO1D793
  3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

|  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882 |
|--|--|
- 
- |                              |  |
|------------------------------|--|
| b) Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
|------------------------------|--|
- 
- | c) Price(s) and volume(s) | <table border="0"> <thead> <tr> <th style="text-align: left;">Price(s)</th> <th style="text-align: left;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.18</td> <td>1,497.674</td> </tr> <tr> <td>£16.18</td> <td>776.283</td> </tr> <tr> <td>£16.18</td> <td>2,556.747</td> </tr> </tbody> </table> | Price(s) | Volume(s) | £16.18 | 1,497.674 | £16.18 | 776.283 | £16.18 | 2,556.747 |
|---------------------------|---|----------|-----------|--------|-----------|--------|---------|--------|-----------|
| Price(s)                  | Volume(s)   |          |           |        |           |        |         |        |           |
| £16.18                    | 1,497.674   |          |           |        |           |        |         |        |           |
| £16.18                    | 776.283   |          |           |        |           |        |         |        |           |
| £16.18                    | 2,556.747   |          |           |        |           |        |         |        |           |
- 
- |                           |                     |
|---------------------------|---------------------|
| d) Aggregated information | 4,830.704<br>£16.18 |
|---------------------------|---------------------|
- 
- |                         |  |
|-------------------------|--|
| Aggregated volume Price |  |
|-------------------------|--|
- 
- e) Date of the transaction 2017-07-14
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/  
amendment Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

- |                           |          |           |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
|                           | £16.18   | 1,165.640 |
|                           | £16.18   | 1,492.989 |

- |                           |           |
|---------------------------|-----------|
| d) Aggregated information | 2,658.629 |
| Aggregated volume Price   | £16.18    |

- e) Date of the transaction 2017-07-14  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Debruyne  
 b) Position/status President, Global Vaccines  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

|                              |  |          |           |        |         |        |         |
|------------------------------|--|----------|-----------|--------|---------|--------|---------|
|                              | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |          |           |        |         |        |         |
| b) Nature of the transaction |  |          |           |        |         |        |         |
| c) Price(s) and volume(s)    | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.18</td> <td>298.166</td> </tr> <tr> <td>£16.18</td> <td>375.805</td> </tr> </table>                                  | Price(s) | Volume(s) | £16.18 | 298.166 | £16.18 | 375.805 |
| Price(s)                     | Volume(s)  |          |           |        |         |        |         |
| £16.18                       | 298.166  |          |           |        |         |        |         |
| £16.18                       | 375.805  |          |           |        |         |        |         |
| d) Aggregated information    | 673.971  |          |           |        |         |        |         |
| Aggregated volume Price      | £16.18   |          |           |        |         |        |         |
| e) Date of the transaction   | 2017-07-14   |          |           |        |         |        |         |
| f) Place of the transaction  | n/a  |          |           |        |         |        |         |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr S Dingemans
  - b) Position/status Chief Financial Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

|  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882 |
|--|--|

|                              |  |          |           |        |           |        |           |
|------------------------------|--|----------|-----------|--------|-----------|--------|-----------|
|                              | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |          |           |        |           |        |           |
| b) Nature of the transaction |  |          |           |        |           |        |           |
| c) Price(s) and volume(s)    | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.18</td> <td>2,535.105</td> </tr> <tr> <td>£16.18</td> <td>2,745.620</td> </tr> </table>                              | Price(s) | Volume(s) | £16.18 | 2,535.105 | £16.18 | 2,745.620 |
| Price(s)                     | Volume(s)  |          |           |        |           |        |           |
| £16.18                       | 2,535.105  |          |           |        |           |        |           |
| £16.18                       | 2,745.620  |          |           |        |           |        |           |
| d) Aggregated information    |  |          |           |        |           |        |           |

|   |  |          |           |        |         |        |         |
|---|--|----------|-----------|--------|---------|--------|---------|
| Aggregated volume Price   | 5,280.725<br>£16.18  |          |           |        |         |        |         |
| e) Date of the transaction  | 2017-07-14   |          |           |        |         |        |         |
| f) Place of the transaction   | n/a  |          |           |        |         |        |         |
| 1. Details of PDMR/person closely associated with them ('PCA')  |  |          |           |        |         |        |         |
| a) Name   | Mr N Hirons  |          |           |        |         |        |         |
| b) Position/status  | SVP, Global Ethics & Compliance  |          |           |        |         |        |         |
| c) Initial notification/<br>amendment   | Initial notification   |          |           |        |         |        |         |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  |  |          |           |        |         |        |         |
| a) Name   | GlaxoSmithKline plc  |          |           |        |         |        |         |
| b) LEI  | 5493000HZTVUYLO1D793   |          |           |        |         |        |         |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |  |          |           |        |         |        |         |
| a) Description of the financial instrument  | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882   |          |           |        |         |        |         |
| b) Nature of the transaction  | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |          |           |        |         |        |         |
| c) Price(s) and volume(s)   | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.18</td> <td>565.161</td> </tr> <tr> <td>£16.18</td> <td>615.859</td> </tr> </table>                                  | Price(s) | Volume(s) | £16.18 | 565.161 | £16.18 | 615.859 |
| Price(s)  | Volume(s)  |          |           |        |         |        |         |
| £16.18  | 565.161  |          |           |        |         |        |         |
| £16.18  | 615.859  |          |           |        |         |        |         |
| d) Aggregated information   | 1,181.020<br>£16.18  |          |           |        |         |        |         |
| Aggregated volume Price   |  |          |           |        |         |        |         |
| e) Date of the transaction  | 2017-07-14   |          |           |        |         |        |         |
| f) Place of the transaction   | n/a  |          |           |        |         |        |         |
| 1. Details of PDMR/person closely associated with them ('PCA')  |  |          |           |        |         |        |         |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr S A Hussain  
 b) Position/status President, Global Pharmaceuticals  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.18   | 2,649.200 |
| £16.18   | 2,985.991 |
- d) Aggregated information 5,635.191  
 Aggregated volume Price £16.18
- e) Date of the transaction 2017-07-14  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern  
 b) Position/status Chief Strategy Officer  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction  
 Increase in notional interest  
 in Ordinary Shares following  
 the re-investment of  
 dividends paid to  
 shareholders on 13 July 2017  
 on Ordinary Shares held in  
 the Company's 2009  
 Performance Share Plan.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.18   | 927.212   |
| £16.18   | 1,082.411 |

- d) Aggregated information 2,009.623  
 Aggregated volume Price £16.18

- e) Date of the transaction 2017-07-14  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas  
 b) Position/status SVP, HR  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| £16.18   | 1,236.288 |
| £16.18   | 1,362.348 |

d) Aggregated information  
Aggregated volume Price

2,598.636  
£16.18

e) Date of the transaction 2017-07-14  
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson  
b) Position/status President, Global Affairs  
Initial  
c) notification/ Initial notification  
amendment

Details of the issuer, emission allowance  
2. market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument  
Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in



|                              |   |           |
|------------------------------|---|-----------|
|                              | the Company's 2009<br>Performance Share Plan. |           |
|                              | Price(s)                                      | Volume(s) |
| c) Price(s) and<br>volume(s) | £16.18  | 715.284   |
|                              | £16.18  | 783.821   |

|                              |           |
|------------------------------|-----------|
| d) Aggregated<br>information | 1,499.105 |
| Aggregated<br>volume Price   | £16.18    |

e) Date of the transaction 2017-07-14

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance  
 b) Position/status President, R&D  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument  
 Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction  
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

|                              |          |           |
|------------------------------|----------|-----------|
|                              | Price(s) | Volume(s) |
| c) Price(s) and<br>volume(s) | £16.18   | 2,571.481 |
|                              | £16.18   | 3,172.607 |

|                           |           |
|---------------------------|-----------|
| d) Aggregated information |           |
| Aggregated volume Price   | 5,744.088 |
|                           | £16.18    |

- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.18   | 158.334   |
| £16.18   | 149.637   |
- d) Aggregated information
- |                   |         |
|-------------------|---------|
| Aggregated volume | 307.971 |
| Price             | £16.18  |
- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: July 17, 2017

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc